These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Search MEDLINE/PubMed
Title: Involvement of spinal kappa opioid receptors in the antinociception produced by intrathecally administered corticotropin-releasing factor in mice. Author: Song ZH, Takemori AE. Journal: J Pharmacol Exp Ther; 1990 Aug; 254(2):363-8. PubMed ID: 2166788. Abstract: Corticotropin-releasing factor (CRF), a putative stress transmitter, in previous studies failed to show any antinociceptive effect after central intracerebroventricular administration. In this study, a possible role of intrathecally (i.t.) administered CRF in modulating nociception and the involvement of opioid receptors were examined. CRF (i.t.) produced a dose-dependent antinociceptive effect in the mouse abdominal stretching (writhing) assay, with an ED50 of 22.1 (18.9-25.8) pmol/mouse. This antinociceptive effect of CRF peaked from 10 min to 1 hr after i.t. administration, although a significant antinociceptive effect was still observable 4 hr after injection. The dose-response curve of CRF antinociception was shifted to the right by i.t. administered alpha-helical CRF (9-41), a CRF antagonist, and the ED50 was raised by 3.7-fold. Naloxone, an opioid antagonist, also dose-dependently shifted the antinociceptive dose-response curve of CRF to the right. Naloxone at 1 and 10 mg/kg s.c. increased the ED50 value of CRF by 2- and 4-fold, respectively. In contrast, s.c. injection of 10 mg/kg of (+)-naltrexone, an inactive enantiomer of naltrexone, did not affect significantly the antinociception of i.t. administered CRF. Intrathecal injection of nor-binaltorphimine, a highly selective kappa opioid antagonist, increased the antinociceptive ED50 of CRF by 5.6-fold. However, the antinociceptive activity of CRF (i.t.) was not significantly affected by either beta-funaltrexamine, an irreversible mu selective opioid antagonist, or naltrindole, a highly selective delta opioid antagonist. Furthermore, the antinociceptive ED50 of CRF was not altered by (+)-1-nor-binaltorphimine, an inactive enantiomer of nor-binaltorphimine.(ABSTRACT TRUNCATED AT 250 WORDS)[Abstract] [Full Text] [Related] [New Search]